Regeneus Ltd. (AU:RGS) has released an update.
Cambium Bio Limited, formerly known as Regeneus Limited, has successfully raised A$3.48 million through a strategic share placement at a 20% premium, with significant investments from leading pharmaceutical entities such as Orient EuroPharma and Zheng Yang Biomedical Technology. The funds are earmarked for advancing nonclinical studies and preparing for Phase 3 trials of Elate Ocular, their novel treatment for dry eye disease, alongside bolstering the company’s working capital for ongoing operations.
For further insights into AU:RGS stock, check out TipRanks’ Stock Analysis page.
